DE60030621D1 - DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors - Google Patents

DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors

Info

Publication number
DE60030621D1
DE60030621D1 DE60030621T DE60030621T DE60030621D1 DE 60030621 D1 DE60030621 D1 DE 60030621D1 DE 60030621 T DE60030621 T DE 60030621T DE 60030621 T DE60030621 T DE 60030621T DE 60030621 D1 DE60030621 D1 DE 60030621D1
Authority
DE
Germany
Prior art keywords
tissue
specific expression
dna construct
blood clotting
clotting factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030621T
Other languages
English (en)
Other versions
DE60030621T2 (de
Inventor
Claude Dr Negrier
Marie Helene Rodriguez
Nathalie Enjolras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
ZLB Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZLB Behring GmbH filed Critical ZLB Behring GmbH
Publication of DE60030621D1 publication Critical patent/DE60030621D1/de
Application granted granted Critical
Publication of DE60030621T2 publication Critical patent/DE60030621T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60030621T 1999-04-27 2000-04-08 DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors Expired - Lifetime DE60030621T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99107397A EP1048736A1 (de) 1999-04-27 1999-04-27 DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors
EP99107397 1999-04-29

Publications (2)

Publication Number Publication Date
DE60030621D1 true DE60030621D1 (de) 2006-10-26
DE60030621T2 DE60030621T2 (de) 2007-09-27

Family

ID=8237961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030621T Expired - Lifetime DE60030621T2 (de) 1999-04-27 2000-04-08 DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors

Country Status (11)

Country Link
US (1) US6884616B1 (de)
EP (2) EP1048736A1 (de)
JP (1) JP4373578B2 (de)
KR (1) KR100681719B1 (de)
AT (1) ATE339510T1 (de)
AU (1) AU779437B2 (de)
CA (1) CA2304376C (de)
DE (1) DE60030621T2 (de)
DK (1) DK1048726T3 (de)
ES (1) ES2270758T3 (de)
PT (1) PT1048726E (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755652B1 (de) 2004-03-19 2010-11-24 Baxter International Inc. Faktor ixa zur behandlung von blutungsstörungen
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
BR112015009229B1 (pt) * 2012-10-24 2021-07-20 Platelet Targeted Therapeutics, Llc Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678282B1 (fr) * 1991-06-28 1994-08-26 Commissariat Energie Atomique Sequences amplificateur et silenceur isolees du promoteur de la gpiib, et leurs applications.
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie
US6066778A (en) * 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage

Also Published As

Publication number Publication date
US6884616B1 (en) 2005-04-26
EP1048735B1 (de) 2006-09-13
KR20010020795A (ko) 2001-03-15
CA2304376A1 (en) 2000-10-29
JP2000333687A (ja) 2000-12-05
ES2270758T3 (es) 2007-04-16
CA2304376C (en) 2010-06-01
AU3019500A (en) 2000-11-02
DK1048726T3 (da) 2006-11-20
JP4373578B2 (ja) 2009-11-25
EP1048735A1 (de) 2000-11-02
AU779437B2 (en) 2005-01-27
KR100681719B1 (ko) 2007-02-15
DE60030621T2 (de) 2007-09-27
ATE339510T1 (de) 2006-10-15
PT1048726E (pt) 2006-12-29
EP1048736A1 (de) 2000-11-02

Similar Documents

Publication Publication Date Title
DE69805772D1 (de) Stabilisierte mischung auf fibrinogenbasis
DK1100880T3 (da) Urat oxidase
ATE199938T1 (de) Adenovirus-aav zwittervirus sowieverfahrungen zur verwendung davon
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
ZA200309030B (en) Removal of plasmin (ogen) from protein solutions
WO2004024300A8 (en) Ultrafiltration membrane, device, bioartificial organ and methods
DE60311731D1 (de) Verfahren zur rekombinanten Herstellung von Antifusogenikpeptide
EA200600746A1 (ru) Конструкции нуклеиновых кислот
DE60144145D1 (de) Subtilisin-variante
NO981044L (no) Sirkulært DNA-molekyl med kondisjonell replikasjonsopprinnelse, dets fremstilling og anvendelse derav i genterapi
AU4691589A (en) Feline infectious peritonitis virus diagnostic tools
DE60207490D1 (de) Verfahren zur Herstellung von (Meth)Acrylsäureanhydrid
DE60030621D1 (de) DNA-Konstrukt zur gewebespezifischen Expression eines Blutkgerinnungsfaktors
DE50208306D1 (de) Verfahren zur Herstellung von nicht-proteinogenen L-Aminosäuren
DK0969877T3 (da) Fremgangsmåder til modulering af væksten af collaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
DE60220281D1 (de) Verfahren zur herstellung von reduziertem coenzym q10
DK1205542T3 (da) L-aminosyre-oxidase fra Rhodococcus arter
ATE512217T1 (de) 5-substituerte hydantoin racemase, dafür kodierende dna, und verfahren zur herstellung optisch aktiver aminosäure
DE60206056D1 (de) Herstellung von polymerteilchen
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
DE50100315D1 (de) Verfahren zur Herstellung von 2,3,5-Trimethyl-p-benzochinon
ATE286746T1 (de) Proteinhaltige hydrogele
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CSL BEHRING GMBH, 35041 MARBURG, DE

8364 No opposition during term of opposition